Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by josameyeron Nov 27, 2011 10:27am

368 Views

Post# 19269839

Broadway loan between Callais from Brigus

The Broadway loan extention for 10.4 million plus interest expires on Dec 1,2011.It is secured by Colorado assets. This is the loan between Callais and Brigus.It will be interesting to see what will happen.Looking forward to the new N-43-101 numbers for zone 147 and the contact zone. to be announced by mid December .I am disappointed by the current price of Brigus.I hope it will change for the better.As always DYOdd. Cheers to all Josa.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features